以免疫检查点抑制剂（ICI）为主的免疫治疗已经成为实体瘤治疗的主要手段，广谱且有效，但随之产生的毒性，或称 为免疫相关不良反应（irAE），越来越成为免疫治疗的障碍。目前多部指南或共识对irAE 的诊断、分级、治疗和监测提出了原则性 和针对性的指导意见。考虑到irAE 的管理往往涉及多学科问题，中国临床肿瘤学会（CSCO）免疫治疗专家委员会、CSCO 抗肿瘤药物安全管理专家委员会组织专家撰写了《免疫检查点抑制剂相关的毒性多学科诊疗协作组建设中国专家共识》并顺利发表。 作为执笔人，现对共识内容进行初步解读。

Immunotherapy, based on immune checkpoint inhibitors (ICIs), has become the mainstay of treatment for solid tumors, with broad spectrum and definitive efficacy; however, the subsequent immune-related toxicity, namely immune-related adverse event (irAE), has increasingly become an obstacle to immunotherapy. At present, several guidelines or consensus have provided principled and specific guidance on the diagnosis, classification, treatment, and monitoring of irAE. Considering the management of irAE often involves multiple disciplines, the Chinese Society of Clinical Oncology (CSCO) immunotherapy committee, Antitumor Drug Safety Management Committee organized a panel of clinical experts and published“Chinese Consensus on the Construction of Multidisciplinary Team for Management of Immune Checkpoint Inhibitor-Related Toxicity”.As the author of the consensus, I hereby make a preliminary interpretation of the content of the consensus.

国家自然科学基金面上项目（No.81572875）；山东省自 然科学基金面上项目（No.ZR202102190539）；CSCO领航肿瘤研究基金 项目（No.Y-2019AZMS-0440）；CSCO默沙东肿瘤研究基金项目（No.Y-MSD2020-0350）；吴阶平医学研究基金项目（No.320.6750.2020-12-16）